Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

– First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients –

– Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments –

See more here